Kyntra Bio, Inc. (KYNB) Stock

About Kyntra Bio, Inc.

Kyntra Bio, Inc. is led by CEO Thane Wettig, publicly traded since 2014.

Kyntra Bio, Inc. (KYNB) stock trades at $4.58 with a market capitalization of $18.55M. The stock is valued at a price-to-earnings (P/E) ratio of 0.08, a negative price-to-book of -0.65, reflecting negative shareholders' equity, price-to-sales of 4.25. Over the past 52 weeks the stock has ranged between $4.58 and $11.65, and currently trades 60.7% below its 52-week high.

On profitability, Kyntra Bio, Inc. generates a return on equity (ROE) of -605.53% (negative, reflecting a net loss), return on capital employed of -78.16%, an operating margin of -766.67%, a net profit margin of 3050.00%.

Kyntra Bio, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Kyntra Bio, Inc. reported revenue of $180.0M rising to $6.0M, a change of -96.7% across 10 years. Compounded, revenue has grown -49.1% a year over five years, -65.1% over three, -80.0% over the last twelve months. Net profit rose to $183.0M.

Operating margin went from -29.9% in 2016 to -712.7% in 2025, a fall of 682.8 percentage points. The most recent net margin is 3050.00%. On a trailing twelve-month basis to Jun '26, revenue is $5.0M and net profit $183.0M.

Borrowings fell from $97.0M to $0, cash from operations was $-5.0M in the latest year, positive in 2 of the last 10.

Return on equity has averaged 162.3% over five years, and was -610.0% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Kyntra Bio, Inc. (KYNB) — frequently asked questions